Joel S Parker

31PUBLICATIONS
225CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Phylogeny and comparative analysisCancer cell biologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Jul 17, 2024
Type II innate lymphoid cell plasticity contributes to impaired reconstitution after allogeneic hematopoietic stem cell transplantation.

Sonia J Laurie, Joseph P Foster, Danny W Bruce

|Jul 12, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.

Antonio Llombart-Cussac, Jose Pérez-García, Fara Brasó-Maristany

|Apr 02, 2024
The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.

Yoo Jane Han, Siyao Liu, Ashley Hardeman

|Nov 04, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.

Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet

|Aug 13, 2023
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).

Holly Tovey, Orsolya Sipos, Joel S Parker

Pageof 6

Frequent Collaborators

12 joint publications

Charles M Perou

5 joint publications

Katherine A Hoadley

4 joint publications

Lisa A Carey

3 joint publications

Fara Brasó-Maristany